Low-dosage of rituximab in Chinese patients with neuromyelitis optica spectrum disorder
Journal of Neuroimmunology, ISSN: 0165-5728, Vol: 317, Page: 1-4
2018
- 24Citations
- 30Captures
Metric Options: Counts1 Year3 YearSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations24
- Citation Indexes24
- 24
- CrossRef5
- Captures30
- Readers30
- 30
Article Description
Rituximab has been effectively used for treating neuromyelitis optica spectrum disorder (NMOSD) for several years. However those regimens exert a heavy burden on Chinese patients. The aim of our study was to investigate an effectiveness, economic alternatives of RTX. The enrolled patients received different immunosuppressant drugs. Annual relapse rate (ARR), neurological disability (Expanded Disability Status Scale, EDSS), time to the next relapse were evaluated after treatments. Fourteen patients treated with RTX and 37 relapse events from 23 patients treated with traditional immunosuppressant drugs (ISDs) were analyzed in our study. Patients with NMOSD treated with RTX showed a reduction in ARR (2.0 ± 1.8 to 0.2 ± 0.3, p = 0.002) and improve disability (EDSS: 3.7 ± 2.1 to 2.3 ± 2.3, p < 0.001) at last follow-up. Kaplan-Meier analysis indicated that patients treated with RTX had a longer time to next relapse compared with those who were treated with traditional ISDs. Our regimens of RTX treatment were effective in NMOSD patients, and exerted a lower risk of adverse events might be lower than did the high-dose RTX regimens. Moreover, our regimen provides an economic and convenient alternative for NMOSD patients.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/S0165572817304629; http://dx.doi.org/10.1016/j.jneuroim.2018.02.004; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85041521520&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/29501080; https://linkinghub.elsevier.com/retrieve/pii/S0165572817304629; https://dx.doi.org/10.1016/j.jneuroim.2018.02.004
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know